News &amp; Updates

Oral supplementation with 1-kestose in patients with mild to moderate ulcerative colitis helps modulate the gut microbiome, which in turn contributes to clinical improvement, as reported in a study.

03 Feb 2023

PCSK9 inhibitors linked to ocular disorders

Use of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) inhibitors appears to increase the risk of ocular disorders, as shown in a study.

Add-on bevacizumab ups hypertension risk in CRC patients

The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

03 Feb 2023

$Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?$

Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?

Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.

03 Feb 2023

Dietary protein intake positively associated with muscle mass in the elderly

In a cross-sectional study evaluating elderly Chinese adults, high total protein and plant-based protein consumption was associated with higher muscle mass.

Tislelizumab–chemotherapy combo poised as new first-line option for advanced gastric cancer

Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.

03 Feb 2023

Saroglitazar may lower cardiovascular risk in NAFLD

Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.

03 Feb 2023

EULAST: No clear benefits in prescribing long-acting over oral antipsychotics for early-phase schizophrenia

Long-acting injectable antipsychotics (LAIAs) showed no substantial advantage over oral antipsychotics in terms of time to discontinuation in patients with early-phase schizophrenia, the EULAST trial has demonstrated.

03 Feb 2023

Epinephrine improves certain out-of-hospital cardiac arrest survival outcomes

Epinephrine, given either at standard or high dose or in combination with vasopressin during out-of-hospital cardiac arrest (OHCA) resuscitation, leads to more favourable return of spontaneous circulation (ROSC) and survival to hospital admission but not survival to discharge or functional outcome, according to a study.

Antibiotic prophylaxis for primary penile implantation tied to higher infection risk

Antibiotic prophylaxis with vancomycin plus gentamicin alone for primary inflatable penile prosthesis surgery results in a higher risk of infection compared to nonstandard antibiotic regimens, suggests a recent study. On the other hand, antifungal use appears to reduce infection risk.